Atherosclerosis · 2025
TRIM39 reinforces E2-ESR1 signaling through SUMOylation of ESR1 to hinder the progression of aortic dissection.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Deming, Liu Di, Gong Renxi, Liu Zikang, Yang Yalun, Lv Lizhen, Xiao Kuang, Lei Chenggang, Tian Kun, Zhou Qian, Qian Haiyun, Ma Shengwei, Cui Fenghe, Wang Xianghui
Аннотация
BACKGROUND AND AIMS: Aortic dissection (AD) is one of the most dangerous and tricky diseases in the field of cardiovascular surgery, severely affecting public health. Recent studies have found that SUMOylation is linked to the pathogenesis of cardiovascular diseases. However, we know very little about the molecular mechanisms of SUMOylation in AD.
METHODS: Clinical samples of AD and normal aorta were collected for transcriptome sequencing analysis. qPCR and Western blot were utilized to examine the expression of TRIM39 in clinical samples. AD mouse model and cell model were constructed to test the effect of TRIM39 overexpression on the progression of AD. With the help of bioinformatics analysis tools UBIBROWSER, BIOGRID, and GPS-SUMO, the substrate protein ESR1 of TRIM39 was predicted. Combined with CO-IP, we verified whether TRIM39 SUMOylated ESR1 and how SUMOylation affected ESR1 protein.
RESULTS: TRIM39 was greatly downregulated in AD samples, and ESR1 is a downstream target protein of TRIM39. In vivo and in vitro experiments revealed that TRIM39 overexpression alleviated the phenotype of AD by changing the contractile phenotype and cell function of aortic smooth muscle cells, and this process depended on the activation of ESR1 by E2. Mechanistically, TRIM39 mediated the SUMOylation of ESR1, thereby enhancing its protein stability and strengthening E2-ESR1 signaling.
CONCLUSIONS: TRIM39 modifies ESR1 through SUMOylation and enhances its stability, facilitating E2-ESR1 signaling and alleviating AD progression.
METHODS: Clinical samples of AD and normal aorta were collected for transcriptome sequencing analysis. qPCR and Western blot were utilized to examine the expression of TRIM39 in clinical samples. AD mouse model and cell model were constructed to test the effect of TRIM39 overexpression on the progression of AD. With the help of bioinformatics analysis tools UBIBROWSER, BIOGRID, and GPS-SUMO, the substrate protein ESR1 of TRIM39 was predicted. Combined with CO-IP, we verified whether TRIM39 SUMOylated ESR1 and how SUMOylation affected ESR1 protein.
RESULTS: TRIM39 was greatly downregulated in AD samples, and ESR1 is a downstream target protein of TRIM39. In vivo and in vitro experiments revealed that TRIM39 overexpression alleviated the phenotype of AD by changing the contractile phenotype and cell function of aortic smooth muscle cells, and this process depended on the activation of ESR1 by E2. Mechanistically, TRIM39 mediated the SUMOylation of ESR1, thereby enhancing its protein stability and strengthening E2-ESR1 signaling.
CONCLUSIONS: TRIM39 modifies ESR1 through SUMOylation and enhances its stability, facilitating E2-ESR1 signaling and alleviating AD progression.